Literature DB >> 23797273

Diagnostic value of metabolic tumor volume assessed by 18F-FDG PET/CT added to SUVmax for characterization of thyroid 18F-FDG incidentaloma.

Bo Hyun Kim1, Seong-Jang Kim, Heeyoung Kim, Yun Kyung Jeon, Sang Soo Kim, In Joo Kim, Yong Ki Kim.   

Abstract

BACKGROUND: The objective of the study was to investigate whether metabolic tumor volume (MTV) measured by fluorine-18 fluorodeoxyglucose (F-FDG) PET/computed tomography (PET/CT) after stratification of serum thyroid stimulating hormone (TSH) levels could predict malignancy in patients with thyroid F-FDG incidentaloma.
MATERIALS AND METHODS: A total 262 patients with focal thyroid F-FDG incidentaloma undergoing cancer evaluation for nonthyroid cancer or a health checkup were enrolled in this study. We retrospectively evaluated the relationship of the maximum standardized uptake value (SUVmax) and MTV in the prediction of malignant thyroid F-FDG incidentaloma.
RESULTS: The prevalence of malignancy was 20.9% (37/177). Malignant thyroid incidentaloma had a statistically significant higher value of SUVmax (malignant: median 4.6, range 1.9-34.9; benign: median 4.1, range 0-28; P=0.030). The value of MTV4 in malignant thyroid incidentaloma was significantly higher than that of benign thyroid incidentaloma (malignant: median 0.16, range 0.02-1.19; benign: median 0.10, range 0-0.65; P=0.032). However, the values of MTV3.5, MTV3, and MTV2.5 did not differ significantly between the groups. After stratification of serum TSH levels (an SUVmax>5 was used as the cutoff point) the sensitivity and specificity for prediction of malignancy were found to be 61.1% [95% confidence interval (CI): 35.7-82.7%] and 68.7% (95% CI: 56.2-79.4%), respectively. The area under the curve (AUC) was 0.655 (95% CI: 0.545-0.755; P=0.0239). When MTV4 greater than 0.07 cm was used as the cutoff point, the sensitivity and specificity for prediction of malignancy were 81.2% (95% CI: 54.4-96.0%) and 50.0% (95% CI: 37.0-63.0%), respectively. The AUC was 0.650 (95% CI: 0.534-0.755; P=0.0451). On comparison receiver operating characteristic curve analysis, no significant difference was found between SUVmax and MTV4 in the prediction of thyroid carcinoma (P=0.4346). However, a combination of SUVmax and MTV4 resulted in an AUC of 0.669 (95% CI: 0.554-0.772; P=0.0183).
CONCLUSION: The SUVmax and MTV4 measured by F-FDG PET/CT after stratification of serum TSH levels could predict thyroid cancer in patients with thyroid F-FDG incidentaloma. A combination of SUVmax and MTV4 may be more useful for the differentiation of malignant from benign thyroid incidentaloma.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23797273     DOI: 10.1097/MNM.0b013e328362d2d7

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  11 in total

1.  Correlation of BRAFV600E Mutation and Glucose Metabolism in Thyroid Cancer Patients: An ¹⁸F-FDG PET Study.

Authors:  James Nagarajah; Alan L Ho; R Michael Tuttle; Wolfgang A Weber; Ravinder K Grewal
Journal:  J Nucl Med       Date:  2015-03-26       Impact factor: 10.057

2.  Role of multi-modality functional imaging in differentiation between benign and malignant thyroid 18F-fluorodeoxyglucose incidentaloma.

Authors:  H Shi; Z Yuan; C Yang; J Zhang; C Liu; J Sun; X Ye
Journal:  Clin Transl Oncol       Date:  2019-03-29       Impact factor: 3.405

3.  Risk of malignancy in thyroid incidentalomas identified by fluorodeoxyglucose-positron emission tomography.

Authors:  A Reum Chun; Hye Min Jo; Seoung Ho Lee; Hong Woo Chun; Jung Mi Park; Kyu Jin Kim; Chan Hee Jung; Ji Oh Mok; Sung Koo Kang; Chul Hee Kim; Bo Yeon Kim
Journal:  Endocrinol Metab (Seoul)       Date:  2014-07-18

4.  Evaluating Focal 18F-FDG Uptake in Thyroid Gland with Radiomics.

Authors:  Ayşegül Aksu; Nazlı Pınar Karahan Şen; Emine Acar; Gamze Çapa Kaya
Journal:  Nucl Med Mol Imaging       Date:  2020-07-28

5.  Risk of malignancy in focal thyroid lesions identified by (18)F-fluorodeoxyglucose positron emission tomography or positron emission tomography/computed tomography: evidence from a large series of studies.

Authors:  Ning Qu; Ling Zhang; Zhong-wu Lu; Wen-jun Wei; Yan Zhang; Qing-hai Ji
Journal:  Tumour Biol       Date:  2014-03-13

6.  High metabolic tumor volume and total lesion glycolysis are associated with lateral lymph node metastasis in patients with incidentally detected thyroid carcinoma.

Authors:  Bo Hyun Kim; Seong-Jang Kim; Keunyoung Kim; Heeyoung Kim; So Jung Kim; Won Jin Kim; Yun Kyung Jeon; Sang Soo Kim; Yong Ki Kim; In Joo Kim
Journal:  Ann Nucl Med       Date:  2015-06-25       Impact factor: 2.668

7.  Diagnostic Value of Volume-Based Fluorine-18-Fluorodeoxyglucose PET/CT Parameters for Characterizing Thyroid Incidentaloma.

Authors:  Huazheng Shi; Zuguo Yuan; Zheng Yuan; Chunshan Yang; Jian Zhang; Yi Shou; Wenrui Zhang; Zhaofu Ping; Xin Gao; Shiyuan Liu
Journal:  Korean J Radiol       Date:  2018-02-22       Impact factor: 3.500

8.  Characterization of focal hypermetabolic thyroid incidentaloma: An analysis with F-18 fluorodeoxyglucose positron emission tomography/computed tomography parameters.

Authors:  Haejun Lee; Yoo Seung Chung; Joon-Hyop Lee; Ki-Young Lee; Kyung-Hoon Hwang
Journal:  World J Clin Cases       Date:  2022-01-07       Impact factor: 1.337

9.  Focal Thyroid Incidentalomas on 18F-FDG PET/CT: A Systematic Review and Meta-Analysis on Prevalence, Risk of Malignancy and Inconclusive Fine Needle Aspiration.

Authors:  J F de Leijer; M J H Metman; A van der Hoorn; A H Brouwers; S Kruijff; B M van Hemel; T P Links; H E Westerlaan
Journal:  Front Endocrinol (Lausanne)       Date:  2021-10-20       Impact factor: 5.555

10.  Early prediction of lenvatinib treatment efficacy by using 18F-FDG PET/CT in patients with unresectable or advanced thyroid carcinoma that is refractory to radioiodine treatment: a protocol for a non-randomized single-arm multicenter observational study.

Authors:  Satoshi Takeuchi; Tohru Shiga; Kenji Hirata; Jun Taguchi; Keiichi Magota; Shin Ariga; Tomohiro Gouda; Yoshihito Ohhara; Rio Homma; Yasushi Shimizu; Ichiro Kinoshita; Yasushi Tsuji; Akihiro Homma; Hiroaki Iijima; Nagara Tamaki; Hirotoshi Dosaka-Akita
Journal:  BMJ Open       Date:  2018-08-30       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.